| Bioactivity | Asfotase alfa (ENB-0040) is a bone-targeted genetically engineered glycoprotein. Asfotase alfa increases the survival rate, bone mineralization and bone length and prevents mineralization defects of the feet, rib cage, lower limbs, jaw bones in Akp2−/− knockout mice. Asfotase alfa can be used for the research of perinatal, infantile, and juvenile-onset hypophosphatasia (HPP)[1]. |
| In Vivo | Asfotase alfa (0.5-8.2 mg/kg; s.c. once daily for 43 days) shows dose-response relationships that strongly support the pharmacological efficacy for HPP[1]. Animal Model: |
| Name | Asfotase alfa |
| CAS | 1174277-80-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yadav MC, et al. Dose response of bone-targeted enzyme replacement for murine hypophosphatasia. Bone. 2011 Aug;49(2):250-6. |